✦ LIBER ✦

CN4 COST-EFFECTIVENESS OF ERLOTINIB COMPARED WITH DOCETAXEL FOR THE TREATMENT OF RELAPSED NONSMALL CELL LUNG CANCER (NSCLC) IN THE UK

✍ Scribed by G Lewis; L Morlotti; J Creeden; M Gyldmark; MD Peake

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN77 PHARMACOECONOMIC ANALYSIS OF ERLOT

✍ O Batigun; E Yildirim 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

PCN6: MODELLING THE COST-EFFECTIVENESS O

✍ P Sharplin; UK Bose; J Holmes 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB

PCN12 COST EFFECTIVENESS OF ERLOTINIB IN

✍ E Orlewska; A Szczesna; M Gyldmark; M Szkultecka-Debek 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PCN10 COST-EFFCTIVENESS ANALYSIS OF ERLO

✍ TC Hsia; GC Chang; YM Chen; MC Lin; WC Su; CM Tsai; CM Tsai; L Yang; J Creeden 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PCN77 COST-EFFECTIVENESS ANALYSIS OF ERL

✍ TE Ciuleanu; M Dediu; LN Minea; S Baculea; M Szkultecka-Debek 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

PCN90 Cost-Effectiveness Analysis of Erl

✍ Nguyen, T.T.T.; Yagudina, R.; Kulikov, A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB